基本信息:
- 专利标题： PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS
- 专利标题（中）：药剂脑淀粉样变治疗
- 申请号：EP98923520.5 申请日：1998-05-19
- 公开(公告)号：EP0983222A1 公开(公告)日：2000-03-08
- 发明人： AVERBACK, Paul , GHANBARI, Hossein , BEHESHTI, Iraj , MORSE, David
- 申请人： NYMOX CORPORATION
- 申请人地址： 9900 Boulevard Cavendish, Nr. 306 Saint-Laurent,Quebec H4M 2V2 CA
- 专利权人： NYMOX CORPORATION
- 当前专利权人： NYMOX CORPORATION
- 当前专利权人地址： 9900 Boulevard Cavendish, Nr. 306 Saint-Laurent,Quebec H4M 2V2 CA
- 代理机构： Plougmann, Vingtoft & Partners A/S
- 优先权： US858343 19970519
- 国际公布： WO9852898 19981126
- 主分类号： C07C43/164
- IPC分类号： C07C43/164 ; A61K31/08 ; C07C43/174 ; C07C217/10 ; C07D211/90 ; C07D295/02 ; C07D295/08 ; C07D473/04 ; A61K31/495 ; A61K31/645 ; A61K31/44 ; A61K31/52
摘要：
Formation of cerebral amyloid associated with Alzheimer's disease can be treated or averted using medicaments that are effective in vivo in preventing disruption of dense microspheres (DMS) or in altering the disruption so as to (i) reduce the volume of tissue occupied by redistributed, transformed DMS protein material and its associated injury focus; (ii) reduce the persistence or duration of injury and inflammation associated with the disrupted DMS and redistributed transformed DMS protein material; and/or (iii) increase the digestion and removal of DMS material through the reticuloendothelial system.